About Sarah Boyce
Sarah Boyce is a director at Atrium Therapeutics.
Form D filings name Sarah Boyce as a director at Abcuro.
Sarah Boyce reports to the SEC as a director or officer of 8 public companies, including Contineum Therapeutics (CTNM), Avidity Biosciences (RNAM) and OmniAb (OABI).
Sarah Boyce first appears on SEC filings in 2015.
Experience
This experience comes from Sarah Boyce's profile and from SEC filings. For roles taken from filings, the years are when the filings name Sarah Boyce in the role, so the role may have started earlier or lasted longer.
AI
Atrium Therapeutics, Inc. Current
Chairperson of the Board
2026 – Present · Public company (RNA)
Abcuro, Inc. Current
Director
2024 – Present · Newton, MA
Develops immunotherapies for people with autoimmune diseases and cancer.
CI
Contineum Therapeutics, Inc. Current
Director
2024 – Present · Public company (CTNM)
AI
Avidity Biosciences, Inc.
President and CEO, director
2019 – 2026 · Public company (RNAM)
OI
OmniAb, Inc.
Director
2022 – 2025 · Public company (OABI)
LI
Ligand Pharmaceuticals Inc.
Director
2019 – 2022 · Public company (LGND)
BI
Bruker Cellular Analysis, Inc.
Director
2020 – 2021 · Public company (CELL)
AI
Akcea Therapeutics, Inc.
President and director
2018 – 2019 · Public company (AKCA)
II
Ionis Pharmaceuticals Inc.
Chief Business Officer and Senior Vice President
2015 – 2018 · Public company (IONS)
FL
Forest Laboratories
Vice President - International business strategy and operations
2012 – 2014
AP
Alexion Pharmaceuticals
VP - Nephrology
2010 – 2011
ND
Novartis Vaccines and Diagnostics
Vice President, Global Progam Head Pediatric and Speciality Business (2009 – 2010)
Business Unit Head - Australia and New Zealand (1999 – 2009)
1999 – 2010
Key Colleagues at Startups
The people Sarah Boyce works with at each company, as listed on that company's latest Form D.
Abcuro, Inc. · Form D, Aug 13, 2026
JM
John Martin
Chief Executive Officer and director
Michael Dybbs
Partner, Samsara BioCapital and director
RH
Ron Hunt
Director
Ming Fang
Managing Director, Redmile Group
Mark Pruzanski
Chairman of the Board